[go: up one dir, main page]

WO2004049914A3 - Methods for reacting an antigen masking compound with red blood cells with high efficiency - Google Patents

Methods for reacting an antigen masking compound with red blood cells with high efficiency Download PDF

Info

Publication number
WO2004049914A3
WO2004049914A3 PCT/US2003/038270 US0338270W WO2004049914A3 WO 2004049914 A3 WO2004049914 A3 WO 2004049914A3 US 0338270 W US0338270 W US 0338270W WO 2004049914 A3 WO2004049914 A3 WO 2004049914A3
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
methods
red blood
reacting
masking compound
Prior art date
Application number
PCT/US2003/038270
Other languages
French (fr)
Other versions
WO2004049914A2 (en
Inventor
Adonis Stassinopoulos
Basha Clark
Original Assignee
Cerus Corp
Adonis Stassinopoulos
Basha Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp, Adonis Stassinopoulos, Basha Clark filed Critical Cerus Corp
Priority to AU2003293237A priority Critical patent/AU2003293237A1/en
Publication of WO2004049914A2 publication Critical patent/WO2004049914A2/en
Publication of WO2004049914A3 publication Critical patent/WO2004049914A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods are provided for the reaction of high hematocrit red cells with an activated antigen masking compound. The reaction at high hematocrit provides a more efficient reaction for producing an antigen masked red blood cell. The resulting RBC compositions are of particular use for introduction into an individual in cases where the potential for an immune reaction is high, for example in alloimmunized blood recipients or in trauma situations where the possibility of transfusion of a mismatched unit of blood is higher. The RBC compositions provide a much lower risk of a transfusion associated immune reaction.
PCT/US2003/038270 2002-12-04 2003-12-03 Methods for reacting an antigen masking compound with red blood cells with high efficiency WO2004049914A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003293237A AU2003293237A1 (en) 2002-12-04 2003-12-03 Methods for reacting an antigen masking compound with red blood cells with high efficiency

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US43121302P 2002-12-04 2002-12-04
US43121502P 2002-12-04 2002-12-04
US43121402P 2002-12-04 2002-12-04
US43121602P 2002-12-04 2002-12-04
US60/431,215 2002-12-04
US60/431,216 2002-12-04
US60/431,213 2002-12-04
US60/431,214 2002-12-04

Publications (2)

Publication Number Publication Date
WO2004049914A2 WO2004049914A2 (en) 2004-06-17
WO2004049914A3 true WO2004049914A3 (en) 2005-02-24

Family

ID=32475715

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2003/038262 WO2004050029A2 (en) 2002-12-04 2003-12-03 Novel activated polyethylene glycol compounds
PCT/US2003/038270 WO2004049914A2 (en) 2002-12-04 2003-12-03 Methods for reacting an antigen masking compound with red blood cells with high efficiency
PCT/US2003/038224 WO2004050848A2 (en) 2002-12-04 2003-12-03 Methods for antigen masking of red blood cells resulting in reduced hemolysis
PCT/US2003/038349 WO2004050897A2 (en) 2002-12-04 2003-12-03 Methods for preparing antigen masked red blood cells having reduced hemolysis by sera

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038262 WO2004050029A2 (en) 2002-12-04 2003-12-03 Novel activated polyethylene glycol compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2003/038224 WO2004050848A2 (en) 2002-12-04 2003-12-03 Methods for antigen masking of red blood cells resulting in reduced hemolysis
PCT/US2003/038349 WO2004050897A2 (en) 2002-12-04 2003-12-03 Methods for preparing antigen masked red blood cells having reduced hemolysis by sera

Country Status (2)

Country Link
AU (4) AU2003293237A1 (en)
WO (4) WO2004050029A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
CN103755949B (en) * 2009-12-25 2016-04-13 天津键凯科技有限公司 Multi-arm polyethylene glycol derivative and with the binding substances of medicine and gel
US20250177448A1 (en) * 2022-03-07 2025-06-05 Icoat Medical Ab New use of peg-phospholipid molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3312685A (en) * 1962-10-30 1967-04-04 Rayonier Inc Solubilizing hydroxyethylcellulose
WO2001091775A2 (en) * 2000-05-31 2001-12-06 Cerus Corporation Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312685B1 (en) * 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3312685A (en) * 1962-10-30 1967-04-04 Rayonier Inc Solubilizing hydroxyethylcellulose
WO2001091775A2 (en) * 2000-05-31 2001-12-06 Cerus Corporation Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US12064537B2 (en) 2017-03-03 2024-08-20 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US12214092B2 (en) 2017-12-29 2025-02-04 Cerus Corporation Systems and methods for treating biological fluids
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12343436B2 (en) 2019-06-28 2025-07-01 Cerus Corporation System and methods for implementing a biological fluid treatment device

Also Published As

Publication number Publication date
AU2003293237A1 (en) 2004-06-23
WO2004050897A2 (en) 2004-06-17
WO2004050897A3 (en) 2004-08-26
AU2003298827A1 (en) 2004-06-23
AU2003298827A8 (en) 2004-06-23
AU2003302499A8 (en) 2004-06-23
WO2004050848A2 (en) 2004-06-17
AU2003297614A8 (en) 2004-06-23
AU2003302499A1 (en) 2004-06-23
AU2003297614A1 (en) 2004-06-23
WO2004050029A2 (en) 2004-06-17
WO2004049914A2 (en) 2004-06-17
AU2003293237A8 (en) 2004-06-23
WO2004050848A3 (en) 2004-12-09
WO2004050029A3 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2001074158A3 (en) Systems and methods for collecting leukocyte-reduced blood components, including plasma that is free or virtually free of cellular blood species
WO2003033046A3 (en) Blood processing systems and methods that alternate flow of blood component and additive solution through an in-line leukofilter
WO2004049914A3 (en) Methods for reacting an antigen masking compound with red blood cells with high efficiency
AU3755200A (en) Platelet collection system
CA2407961A1 (en) Automated system and method for withdrawing compounds from blood
WO2003076490A8 (en) Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
AU2003301200A1 (en) Device and process for the preparation of autologous thrombin serum
CA2220295A1 (en) Blood collection and separation system
AU2003294787A1 (en) Method and device for separating whole blood into an erythrocyte concentrate and cell-free or thrombocyte-containing plasma under gravitational force
AU2003269820A1 (en) Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods
WO2006129312A3 (en) Automated cell therapy system
AU2003214752A1 (en) Method and device for the removal of partially protein bound substances
WO2004024300A8 (en) Ultrafiltration membrane, device, bioartificial organ and methods
AU2003217111A1 (en) Fluid transfer assembly
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
WO2005021706A3 (en) Delivery of compounds with rehydrated blood cells
WO2003047650A3 (en) Preparation of red blood cells having reduced immunogenicity
WO2001091775A3 (en) Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
AU2003292172A1 (en) Filter
WO2005030040A8 (en) Hematopoietic stem cell identification and isolation
IE791583L (en) Discriminating red blood cells from platelets
EP1075844A3 (en) Device and method for autologous blood transfusion
ATE321579T1 (en) DEVICE FOR SEPARATING BLOOD INTO INDIVIDUALS AND/OR GROUPS OF ITS COMPONENTS
DE60213852D1 (en) PREPARATION OF CELL SUSPENSIONS
EP0690125A3 (en) Process for induction culture of cytotoxict lymphocytes having killing activity against tumor cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP